B+
Bull case
20%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-07-14 · RankAlpha Sentiment Codex
SINT
SINTXDNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-07-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-07-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-07-14
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+37.8
Score
AI commentary
The packet shows sparse, low-buzz news flow and no usable analyst revision or target-change evidence. Primary-source evidence supports a real product/commercialization strategy and a balance-sheet transaction, but forward visibility remains weak; sentiment is neutral-to-cautious rather than bullish.
RankAlpha Sentiment Codex - 2026-07-14
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-16catalystCapital-structure transaction and resale-registration deadlineHigh impact
The June 29 letter agreement releases 255,267 shares, replaces 251,987 abeyance shares with a pre-funded warrant, and replaces an existing warrant with a 1,268,135-share warrant at $2.14; the company expects improved stockholders’ equity, but dilution and warrant overhang remain material [#8-K-2026-07-02].
2026-12-31eventSINAPTIC foot-and-ankle commercialization proofHigh impact
FDA clearance and initial OsseoSculpt revenue provide a product platform, but the key unresolved milestone is measurable launch, adoption, and recurring revenue rather than additional regulatory validation [#PR-EARNINGS-2025-11-13].
2026-12-31catalystPartnering and adjacent biomaterials expansionHigh impact
Management identified partnering, licensing, KOL engagement, and polymer-composite applications as routes to broaden market access; visibility is limited and no dated agreement is confirmed in the packet [#PR-EARNINGS-2025-11-13].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-14 • Updated nightlySource: Internal modelMethodology